As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...

Eli Lilly and Novo Nordisk already make popular GLP-1s in the Triangle. A Swiss drugmaker says its future Wake County site ...

Burke Wealth Management, an investment management company, released its “Focused Growth Strategy” second-quarter 2025 ...

Eli Lilly’s (NYSE:LLY) stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street. In a key late-stage trial ...

The Trump administration’s sweeping tariffs have sent ripples through the healthcare sector in 2025. Last week, the US ...

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to invest in for long-term growth. Eli Lilly and Company (NYSE:LLY ...

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

Can Novo Nordisk and Eli Lilly regain their former stock market glory? A lot is riding on next year's pills ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

A powerful new medication is being hailed as the 'Godzilla' of weight-loss shots. It has been suggested retatrutide can help people shed a quarter of their body weight in under a year - almost twice ...

The drug, which is estimated to be taken by up to 750,000 people, is one of the country's most popular weight loss and ...